Publication: A human single chain transbody specific to matrix protein (M1) interferes with the replication of influenza a virus
Issued Date
2010-07-21
Resource Type
ISSN
15204812
10431802
10431802
Other identifier(s)
2-s2.0-77954885702
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Bioconjugate Chemistry. Vol.21, No.7 (2010), 1134-1141
Suggested Citation
Ornnuthchar Poungpair, Anek Pootong, Santi Maneewatch, Potjanee Srimanote, Pongsri Tongtawe, Thaweesak Songserm, Pramuan Tapchaisri, Wanpen Chaicumpa A human single chain transbody specific to matrix protein (M1) interferes with the replication of influenza a virus. Bioconjugate Chemistry. Vol.21, No.7 (2010), 1134-1141. doi:10.1021/bc900251u Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/28670
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
A human single chain transbody specific to matrix protein (M1) interferes with the replication of influenza a virus
Other Contributor(s)
Abstract
A cell penetrating format of human single chain antibody (HuScFv) specific to matrix protein (M1) of influenza A virus was produced by molecular linking of the gene sequence encoding the HuScFv (huscfv) to a protein transduction domain, i.e., penetratin (PEN) of the Drosophila homeodomain. DNA of a recombinant phagemid vector carrying the huscfv was used as a platform template in a three-step PCR for generating a nucleotide sequence encoding a 16 amino acid PEN peptide. The PEN-HuScFv had negligible cytotoxicity on living MDCK cells. They were readily translocated across the cell membrane and bound to native M1 in the A/H5N1-infected cells as revealed by immunofluorescent confocal microscopy. The PEN-HuScFv, when used to treat the influenza virus infected cells, reduced the number of viruses released from the cells. In conclusion, the cell penetrating M1-specific HuScFv, a transbody, produced in this study affected the influenza A virus life cycle in living mammalian cells. While the molecular mechanisms of the PEN-HuScFv need more investigation, the reagent warrants further testing in animals before developing it into a human immunotherapeutic anti-influenza formula. © 2010 American Chemical Society.